Stock CYTO ALTAMIRA THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 16:22:05 14/05/2024 BST 		5-day change 1st Jan Change
1.45 USD +0.69% Intraday chart for Altamira Therapeutics -12.73% -58.62%
05-01 Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation CI
04-24 Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal CI

Valuation

Fiscal Period: December 2019 2023 2024 2025 2026
Capitalization 1 5.174 1.164 2.928 - -
Enterprise Value (EV) 1 3.789 1.164 2.928 2.928 2.928
P/E ratio -0.69 x -0.37 x - - -
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA -715,778 x - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 8.26 398 2,240 - -
Reference price 2 626.7 2.927 1.307 1.307 1.307
Announcement Date 16/04/20 10/04/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2023 2024 2025 2026
Net sales 1 - - - - -
EBITDA -7.228 - - - -
EBIT 1 -7.259 - -7.846 -10.29 -12.76
Operating Margin - - - - -
Earnings before Tax (EBT) -6.826 - - - -
Net income -6.632 -3.869 - - -
Net margin - - - - -
EPS -912.0 -7.880 - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 16/04/20 10/04/24 - - -
1CHF in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 - - - - -
EBITDA - - - - -
EBIT -3.152 - - - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income -3.028 - - - -
Net margin - - - - -
EPS -248.0 - - - -
Dividend per Share - - - - -
Announcement Date 16/04/20 - - - -
1CHF in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position 1.38 - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 3.02 - - - -
Capex / Sales - - - - -
Announcement Date 16/04/20 10/04/24 - - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+4.67% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.34% 105B
BIONTECH SE Stock BioNTech SE
-12.17% 22.34B
ARGENX SE Stock argenx SE
-3.76% 21.93B
GENMAB A/S Stock Genmab A/S
-6.03% 18.59B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.43% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.13% 13.7B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.85% 12.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYTO Stock
  4. CYTO Stock
  5. Financials Altamira Therapeutics